• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Here's How I'm Trading XBiotech

Do these shares get back to the 2020 highs that were reached back in January?
By STEPHEN GUILFOYLE
Aug 24, 2020 | 10:00 AM EDT
Stocks quotes in this article: XBIT, GILD, REGN, LLY

XBiotech. Never heard of them? Well, I mean before today. It was about a week ago that XBiotech (XBIT) announced that the firm had identified "True Human" antibodies that could possibly be used as a therapy in the fight against the SARS-CoV2 virus that causes the disease referred to as Covid-19. Through a collaborative effort with BioBridge Global, which is the parent organization of The South Texas Blood & Tissue Center, and QualTex laboratories, the firm discovered these antibodies.

BioBridge has used XBiotech's screening technology to identify donors who had been infected with this coronavirus with the intention of providing convalescent plasma as a means to treat patients suffering from severe cases of the illness.

Flash Forward

Today. Monday Morning. XBiotech announces that the Food and Drug Administration had issued an emergency use authorization, as you know, for the use of Covid-19 convalescent Plasma as a treatment for those currently suffering from an active infection. BioBridge Global provides blood products to hospitals using XBiotech's screen to identify "effective" plasma. BioBridge then uses that plasma to produce natural immunity in blood meant to treat Covid-19 patients in hospitals.

Remember, the preliminary findings that the FDA based its decision on to make use of convalescent plasma showed an improved survival rate 30 days out of 35% out of 70,000 patients treated over time. There has, as of yet, been no concerning negative safety issues connected to making use of such treatment.

The Chart

Yes, I am long the name. Very small. I bought just a few shares on spec early this morning. The shares took off almost immediately. I did not snare enough for an investment, so normally this would be a trade. May just hang on to it to see where it goes, just out of interest. Only one analyst even follows the name. There is no expectation for profitability, or lack thereof. The one projection for revenue for the current quarter is for $7 million, with $28 million for the full year.

Will that number have to change if this therapeutic becomes useful or perceived by the medical community as useful? Right now, Gilead Sciences' (GILD) Remdesivir is the only other game in town, really, outside of some steroid treatments that have seemed helpful. We all await data on monoclonal antibody treatments still in clinical trials being developed by the likes of Regeneron (REGN) and Eli Lilly (LLY) .

The shares of XBIT will likely crash through the 61.8% retracement level of the year's entire range after the bell rings. Do these shares get back to the 2020 highs that were reached back in January? If they do, I probably won't hold all of them that long. Remember, this is a trade.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle was Long XBIT, REGN equity.

TAGS: Drug Approvals | Investing | Markets | Stocks | Technical Analysis | Trading | Biotechnology | Coronavirus

More from Investing

I Got the 'SOS', So Here's My Take on the Stock's Saga

Timothy Collins
Feb 28, 2021 6:35 PM EST

Let's try to sort out the details of the complicated story of SOS Ltd. -- and why the short reports might be ... selling you short.

Bearish Bets: 2 Nasdaq Stocks You Should Consider Shorting This Week

Bob Lang
Feb 28, 2021 10:30 AM EST

These names are displaying both quantitative and technical deterioration.

Jim Cramer: What History Tells Us About Bond-Rate Scares Like This

Jim Cramer
Feb 27, 2021 2:01 PM EST

We could have some real pain ahead for some stocks. Five different kinds.

What's Next for Bonds, TLT and Interest Rates?

Bruce Kamich
Feb 27, 2021 12:30 PM EST

Thoughts and observations on Treasuries and the direction of interest rates.

Navigating a Market Correction

James "Rev Shark" DePorre
Feb 27, 2021 10:00 AM EST

The most critical factor in long-term market success is the ability to effectively navigate market corrections.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:51 AM EST REAL MONEY

    Watch Bob Lang and Doug Kass Discuss Short-Selling!

    Bob Lang and Doug Kass with an engaging and educat...
  • 11:32 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Navigating a Market Correction
  • 11:29 AM EST GARY BERMAN

    Where Does the Nasdaq Go From Here?

    Where does the Nasdaq Composite (CCMP) index go fr...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login